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Distinct conformational Dynamics  
of Three g Protein-coupled 
receptors Measured Using  
Flash-BreT Biosensors
Kyla Bourque, Darlaine Pétrin, Rory Sleno, Dominic Devost, Alice Zhang  
and Terence E. Hébert*
Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada
A number of studies have profiled G protein-coupled receptor (GPCR) conformation 
using fluorescent biaresenical hairpin binders (FlAsH) as acceptors for BRET or FRET. 
These conformation-sensitive biosensors allow reporting of movements occurring on the 
intracellular surface of a receptor to investigate mechanisms of receptor activation and 
function. Here, we generated eight FlAsH-BRET-based biosensors within the sequence 
of the β2-adrenergic receptor (β2AR) and compared agonist-induced responses to the 
angiotensin II receptor type I (AT1R) and the prostaglandin F2α receptor (FP). Although all 
three receptors had FlAsH-binding sequences engineered into the third intracellular loops 
and carboxyl-terminal domain, both the magnitude and kinetics of the BRET responses 
to ligand were receptor-specific. Biosensors in ICL3 of both the AT1R and FP responded 
robustly when stimulated with their respective full agonists as opposed to the β2AR 
where responses in the third intracellular loop were weak and transient when engaged 
by isoproterenol. C-tail sensors responses were more robust in the β2AR and AT1R but 
not in FP. Even though GPCRs share the heptahelical topology and are expressed in the 
same cellular background, different receptors have unique conformational fingerprints.
Keywords: g protein-coupled receptors, g proteins, conformational profiling, biosensors, signaling
inTrODUcTiOn
Understanding the dynamic nature of G protein-coupled receptors (GPCRs) is critical given their 
capacity to modulate numerous biological responses in health and disease. Largely localized to the 
plasma membrane, GPCRs respond to an array of extracellular stimuli including photons, odors, 
hormones, peptides, lipids, and sugars (1). With over 800 genes expressed in the human genome, 
they are found in nearly every organ of the body (2, 3). The β2-adrenergic receptor (β2AR) is one 
of the most studied GPCRs and is tightly regulated as part of elaborate multicomponent signaling 
networks. Upon ligand binding, the receptor undergoes a conformational change that stimulates 
the exchange of guanine diphosphate for guanine triphosphate in the Gαs subunit leading to the 
functional dissociation of the Gβγ dimer from Gα (1). These G proteins then independently act on 
downstream effector molecules in a number of signaling cascades. This simplified notion of receptor 
activation provides only a glimpse into the complex processes of signal transduction, of which we 
have much to learn.
Understanding GPCR function involves determining how agonist binding translates into recep-
tor activation. The traditional view of receptor activation has evolved from where it was initially 
TaBle 1 | list of primers used for the generation of the β2-adrenergic 
receptor (β2ar) Flash-BreT-based recombinant biosensors.
Position sequence (5′ → 3′)
ICL2 p1 F: TGCTGCCCCGGCTGCTGCAGCCTGCTGA
R: GCAGCAGCCGGGGCAGCACTGGTACTTG
ICL2 p2 F: TGCTGCCCCGGCTGCTGCCCTTTCAAGTACCAGAGC
R: GCAGCAGCCGGGGCAGCATGAAGTAATGGCAAAGTAGC
ICL3 p1 F: TGCTGCCCCGGCTGCTGCCATGTCCAGA
R: GCAGCAGCCGGGGCAGCAGAAGCGGCC
ICL3 p2 F: TGCTGCCCCGGCTGCTGCGAGCAGGATG
R: GCAGCAGCCGGGGCAGCACACCTGGCT
ICL3 p3 F: TGCTGCCCCGGCTGCTGCGGACTCCGCA
R: GCAGCAGCCGGGGCAGCAATGCCCCGT
C-tail p1 F: TGCTGCCCCGGCTGCTGCGCCTATGGGA
R: GCAGCAGCCGGGGCAGCACTTCAAAGA
C-tail p2 F: TGCTGCCCCGGCTGCTGCAATAAACTGC
R: GCAGCAGCCGGGGCAGCATTCTTTCTCC
C-tail p3 F: TGCTGCCCCGGCTGCTGCCATCAAGGTA
R: GCAGCAGCCGGGGCAGCAGCCCACAAA
name sequence (5′ → 3′)
BamHI β2AR F: CAGTGGATCCATGGGGCAACCCGGGAAC
β2AR EcoRI 
BamHI
R: CTCCGGATCCGAATTCCAGCAGTGAGTC
NheI XhoI Kozak 
SP
F: CCTAGCTAGCTCGAGGCCACCATGAA
2
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thought of as a switch from a single inactive state to a single active 
state. Now it is widely accepted that the receptor pool in any 
given cell can occupy a number of different inactive and active 
conformations (4–6). At equilibrium, there are numerous confor-
mations within the receptor population and different orthosteric 
and allosteric ligands can stabilize diverse receptor states. The 
fundamental mechanisms of GPCR activation have been inves-
tigated by several groups using diverse techniques, including 
but not limited to nuclear magnetic resonance, double electron– 
electron resonance, and fluorescence spectroscopy (4, 7–9). Both 
fluorescence and bioluminescence resonance energy transfer 
(FRET and BRET) approaches have also been used to explore 
the conformational dynamics of GPCRs (9–14). The site specific 
introduction of the short tetracysteine motif CCPGCC within 
the coding frame of a receptor when labeled with a fluorescein 
derivative can be used in resonance energy transfer (RET) appli- 
cations to report on conformations adopted by the receptor 
upon ligand binding in living cells (15, 16).
We have explored the use of FlAsH BRET in the conforma-
tional profiling of the prostaglandin F2α receptor [FP; (11)], 
and the angiotensin II type I receptor [AT1R; (17)]. Here, we 
introduced this tetracysteine tag at various locations within the 
coding sequence of the β2AR in order to report on conformational 
changes upon agonist stimulation. Eight such biosensors were 
constructed; two within the second intracellular loop, three in the 
third intracellular loop, and three in the carboxyl terminus of the 
receptor. In a previous study, the β2AR was tagged using FlAsH 
FRET (18). In that work, the third intracellular loop was tagged 
with the FlAsH motif and the carboxyl terminus with CFP after 
having truncated the C-tail at amino acid 343 (18). Upon agonist 
stimulation, an increase in the FRET ratio was observed suggest-
ing that the third intracellular loop approaches the C-terminus 
(18). Other groups have also attempted to understand the 
conformational dynamics of the β2AR while using fluorescence-
based probes as indicators of conformational changes occurring 
in real-time. Lohse and colleagues have generated FRET-based 
biosensors incorporating YFP in the third loop and CFP in the 
C-terminus of the β2AR (19). Again, the receptor was truncated 
at amino acid 369. To our knowledge, our study is the first report 
of using the full-length β2AR tagged with reporter proteins to 
monitor conformations adopted by the receptor upon agonist 
stimulation. Further, we compare and contrast three distinct 
GPCRs and show that even though they share a similar seven 
transmembrane architecture, they behave very differently in 
regards to the magnitude and kinetics of their BRET responses.
MaTerials anD MeThODs
Materials
Primers
All primers were synthesized and purchased by Integrated DNA 
Technologies (Coralville, IA, USA, see Table 1).
Constructs
The recombinant receptors used in this paper are as follows: 
SP-FLAG-hAT1R-CCPGCC-ICL3-p3-RlucII or SP-FLAG-hAT1- 
R-CCPGCC-C-tail-p1-RlucII in a pIRESH plasmid backbone 
(17) along with SP-HA-hFP-CCPGCC-ICL3-p4-RlucII in a 
pcDNA3.1(−) backbone (11), in addition to the panel of eight 
β2AR biosensors expressed in a pIRESpuro3 plasmid backbone.
generation of Flash-BreT-Based 
Biosensors
The intramolecular biosensors were designed to harbor the tet- 
racysteine tag positioned at various locations within the intracel-
lular surface of the receptor in addition to a C-terminally fused 
Renilla luciferase. More precisely, the CCPGCC tag was inserted 
in two positions within the second intracellular loop, three within 
the third, and three within the carboxyl terminus domain of the 
receptor. For ease of cloning, compatible restriction sites were 
introduced by polymerase chain reaction (PCR) at the 5′ and 3′ 
ends of the receptor to facilitate its insertion into its correspond-
ing mammalian expression vector. Briefly, HA-tagged hβ2AR (20) 
in a pcDNA3.1(−) backbone vector was used as a template and 
amplified by PCR using the BamHI-β2AR forward and the β2AR-
EcoRI-BamHI reverse primers. The resulting PCR product was 
cloned into an accepting vector; pIRESpuro3-signal peptide-HA-
RlucII using BamHI. We screened for correct orientation using 
PstI. The introduction of the CCPGCC motif was accomplished 
by overlapping PCR where the wild-type receptor was flanked 
by the appropriate primers (Table 1) in order to introduce the 
desired TC tag within the coding sequence (11). In the first round, 
fragment one was generated using NheI-XhoI-forward primer 
and the appropriate FlAsH internal reverse primer. Fragment 
2 was generated using the appropriate FlAsH internal forward 
primer and β2AR-EcoRI-BamHI reverse primer. Both fragments 
were then combined in equal portions and used as templates for 
the second round of PCR using NheI-XhoI-Kozak-β2AR forward 
and β2AR-EcoRI-BamHI reverse primer. This product was cloned 
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into pIRESpuro3-SP-HA-RlucII backbone using NheI and EcoRI. 
All constructs were confirmed by bidirectional sequencing 
(Génome Québec).
cell culture
HEK 293 SL cells were cultured in Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 5% vol/vol fetal bovine 
serum and 1% w/v penicillin–streptomycin from Wisent. The 
cells were maintained in a controlled environment, 37°C in a 
humidified atmosphere at 95% air and 5% CO2.
Transient Transfection
HEK 293 SL cells were plated at a density of 2.0 × 105 cells per well 
in clear 6-well plates (Thermo Scientific, 140675) prior to trans-
fection. On the following day, cells were transfected with 1 µg of 
each of the eight β2AR FlAsH biosensors along with pcDNA3.1(−) 
for a total of 1.5  µg per well using Lipofectamine 2000 (Invit- 
rogen) following the manufacturer’s instructions. Alternatively, 
1  µg of AT1R-ICL3-p3-RlucII or AT1R-C-tail-p1-RlucII and 
500 ng of the FP-ICL3-p4-RlucII biosensor was also used.
immunofluorescence
The day following transfection, cells were detached with 0.25% 
Trypsin–EDTA (Wisent) and 2.0 × 104 cells were re-plated onto 
a poly-l-ornithine (Sigma-Aldrich) treated clear bottom black 
96-well plate (Thermo Scientific, 165305). The next day, the cells 
were washed once with phosphate-buffered saline (PBS) and 
fixed with 2% paraformaldehyde (Sigma-Aldrich) for 10 min at 
room temperature. Successively, the cells were blocked with a 1% 
bovine serum albumin (Fisher Scientific) PBS solution for 1  h 
at room temperature to prevent non-specific interactions of the 
antibodies. Cells were then incubated with a monoclonal mouse 
anti-HA primary antibody for 1 h (BioLegend, 1:200, previously 
Covance). Afterward, the cells were washed three times with PBS 
and an Alexa fluor-488 goat anti-mouse IgG secondary antibody 
(Life Technologies, 1:1,000) was used to label cells. To confirm 
the ability of recombinant receptors to localize to the cell surface, 
the Operetta High Content Imaging system (Perkin Elmer) with 
a 20× WD objective was used. The excitation filter was set at 
475/15 nm and its corresponding emission filter at 525/25 which 
permitted to capture the signal produced by Alexa fluor-488.
gαs coupling and Downstream  
caMP Production
HEK 293 SL cells were transfected with 1 µg of each of the eight 
β2AR FlAsH biosensors and the β2AR-WT-RlucII construct sup-
plemented with 0.5 µg of the previously described H188 EPAC 
FRET sensor (21) using Lipofectamine 2000 (Invitrogen) follow- 
ing the manufacturer’s instructions. The day following transfec-
tion, cells were detached with 0.25% Trypsin–EDTA (Wisent) 
and 4.0 × 104 cells were re-plated onto a poly-l-ornithine (Sigma-
Aldrich) treated black flat bottom 96-well plate (Costar, 3916). 
The day of the experiment, cells were washed once in 150  µL 
of Krebs buffer and the cells then sat in 90 µL of Krebs at 37°C 
prior to the start of the assay. A Synergy 2 plate reader (Biotek) 
was used to assay coupling of the β2AR FlAsH biosensors to 
Gαs by investigating accumulation of cAMP. The temperature of 
the instrument was set at 37°C and kinetic measurements were 
taken. The 420/50 excitation filter was used to excite the donor 
molecule, mTurquoise2, and light was captured by the emission 
filters 485/20 (mTurquoise2) and 528/20 (Venus). Basal FRET was 
measured continuously every 5 s for a total of 20 s. Cells were then 
treated with either the vehicle (ascorbic acid) or the full agonist, 
10 µM isoproterenol (in ascorbic acid) using the injector module. 
Stimulated FRET readings were then captured every 5 s for a total 
time of 2 min. FRET ratios were computed by dividing the Venus 
emission channel by the mTurquoise2 emission channel. ΔFRET 
ratios were calculated by subtracting the averaged isoproterenol 
stimulated FRET ratio by the averaged basal FRET ratio, as shown; 
ΔFRET = (avgFRETstimulated − avgFRETbasal).
erK1/2 MaP Kinase activation
Twenty-four hours post-transfection, cells were detached with 
0.25% Trypsin–EDTA (Wisent) and 400  µL of cell suspension 
was re-plated onto a clear 12-well plate (Costar, 3513). On the 
day of the experiment, the cells were starved in DMEM without 
serum supplementation for 5 h. Afterward, cells were stimulated 
with either vehicle or 10 µM isoproterenol for 5 min at 37°C. The 
plate was then placed on ice, where the cells were washed once 
with an ice-cold PBS solution. The cells were lysed in 200 µL of 
4× Laemmli buffer (2% SDS, 10% glycerol, 60 mM Tris pH 6.8, 
0.02% bromophenol blue, 5% β-mercaptoethanol). In order to 
shear the genomic DNA, lysates were sonicated three times, each 
repetition for 5 s at 3 W using a Sonicatior 3000 (Misonix). Lysates 
were then heated at 65°C for 15 min.
MAP kinase activation was measured by western blot. 
Correspondingly, 30  µL of cell lysate was loaded and proteins 
were, respectively, separated by SDS-PAGE and then transferred 
onto a PVDF membrane via a wet transfer technique. To prevent 
non-specific binding of the primary antibody, the membrane 
was blocked in a 5% non-fat milk solution in Tris-buffered saline 
and 0.0005% Tween20 solution. An anti-phospho-ERK1/2 rab-
bit primary antibody was used (Cell Signalling Technologies, 
1:1,000) followed by an anti-rabbit polyclonal IgG peroxidase 
secondary antibody (Santa Cruz Biotechnology, 1:20,000). 
Immuno-detection was accomplished via chemiluminescence 
using Western Lightning plus-ECL (Perkin Elmer) or ECL-Select 
western blotting detection reagent (GE Healthcare) given that the 
secondary antibody was conjugated to the horseradish peroxidase 
enzyme.
Flash labeling
Twenty-four hours post-transfection, cells were detached with 
0.25% Trypsin–EDTA (Wisent) and 4.0 × 104 cells were re-plated 
onto a poly-l-ornithine (Sigma-Aldrich) treated white 96-well 
plate (Thermo Scientific, 236105). The next morning, a 25 mM 
solution of 1,2-ethanedithiol (EDT) was prepared by diluting it in 
dimethyl sulfoxide. Then, one volume of FlAsH reagent (2 mM) 
was added to two volumes of EDT to make a 667  µM FlAsH 
(Invitrogen) solution, which was incubated for 10 min at room 
temperature. Following the incubation, 100 µL of Hank’s balan- 
ced salt solution (HBSS) without phenyl red, with sodium bicar-
bonate, calcium, and magnesium was added to the 667 µM FlAsH 
FigUre 1 | Positions of β2-adrenergic receptor (β2ar) conformation-sensitive biosensors. (a) Schematic of the β2AR FlAsH-BRET-based intramolecular 
biosensors. The N-terminus and C-terminus are fused with an HA tag and RlucII, respectively. The FlAsH motif was introduced at specific sites within the second, 
third loop, and carboxyl terminus of the receptor. (B) Positioning of the FlAsH tags within the sequence of the β2AR. The sequence of the receptor is shown in black 
where the position of the FlAsH tag is highlighted in red.
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solution and further incubated for 5  min at room temperature 
(Wisent). Then, HBSS was added to make a solution with final 
concentration of 750  nM FlAsH-EDT2. In parallel, cells were 
washed in 150 µL of HBSS prior to the FlAsH labeling. Subsequen-
tly, 60 µL of the 750 nM FlAsH-EDT2 solution was added to the 
cells and incubated for 1 h at 37°C, protected from any source 
of direct light. Following the incubation, cells were washed once 
with 100 µL of l M 2,3-dimercapto-1-propanol (BAL, Invitrogen) 
diluted in HBSS buffer and then incubated for 10 min at 37°C. 
The cells were washed once again with BAL without incubation. 
Afterward, cells were washed once with 150 µL of the assay buffer: 
Krebs (146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl2, 1 mM CaCl2, 
10 mM HEPES pH 7.4, 0.1% glucose). The cells then sat in 80 µL of 
Krebs for 2 h at room temperature, in an environment protected 
from light, prior to the BRET assay. The FlAsH labeling procedure 
has been previously described elsewhere (11).
BRET Measurements
A TriStar2 LB 942 multimode plate reader from Berthold Tech-
nologies was used to measure BRET using the pre-determined 
BRET1 filter pair F485 and F530. Light was produced via enzymatic 
catalysis of the luciferase substrate coelenterazine h by the donor 
RlucII. Accordingly, 10  µL of a 2  µM coelenterazine h solution 
(NanoLight Technologies) was added to the cells and incubated 
for 5  min whereafter the luminescence was measured. Basal 
BRET corrected from spectral overlap of the donor and acceptor 
channels were calculated by subtracting the BRET value obtained 
from unlabeled cells expressing solely the donor from the corre-
sponding BRET value obtained from the labeled FlAsH recombinant 
receptors. Additionally, ligand-induced changes were investigated 
and kinetic readings were reported. Correspondingly, the count-
ing time of the two filters was analyzed continuously every 0.2 s 
for a total of 50 repeats. Subsequently, either vehicle or a saturating 
concentration of the agonist, 10  µM isoproterenol, was injected 
using the injector module. For the AT1R, 1 µM angiotensin II was 
used and 1 µM PGF2α for FP. Thereafter, the luminescence was 
again captured every 0.2 s and a total of 100 repeats. The change 
in BRET, as a response to the addition of agonist or the ΔBRET, 
as referred to in this paper, was computed by subtracting the 
average BRET across all reads pre-injection from the average BRET 
across all reads post-injection: ΔBRET =  (avgBRETpost-injection) − 
(avgBRETpre-injection).
statistical analysis
All statistical analysis was performed using GraphPad Prism 7.0 
software. Data are reported as mean ±  SE. The Prism software 
performed a Brown–Forsythe test to determine if parame- 
tric or non-parametric statistics should be performed. The degree 
of Gαs coupling was evaluated using a one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test com-
paring the various FlAsH positions to the wild type (Figures 3A,B). 
When determining the basal BRET exhibited by each of the 
recombinant β2AR biosensors, a one-way ANOVA was performed. 
A Dunnett’s post  hoc test was successively completed with the 
purpose of comparing the basal BRET of the eight recombinant 
constructs to the wild-type receptor (Figure 4A). When evaluating 
the agonist-induced BRET response, a two-way ANOVA was car-
ried out followed by a Bonferroni corrected Student’s t-test aimed 
at comparing the response of the vehicle to the response of the 
agonist for each individual sensor position (Figure 4B).
FigUre 2 | cell surface localization of the β2-adrenergic receptor (β2ar) Flash-BreT-based biosensors. Fluorescence microscopy validating  
cell surface localization of the FlAsH-tagged intramolecular β2AR biosensors. Immunofluorescence images of non-permeabilized HEK 293 SL cells transiently 
transfected with the recombinant β2AR constructs demonstrating their membrane localization. The cells were incubated with an anti-HA primary antibody and  
then stained with an Alexa fluor-488 conjugated secondary antibody. Images were taken using the Operetta high content microscope (Perkin Elmer).
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FigUre 3 | Functional characterization of the β2-adrenergic receptor (β2ar) Flash-BreT-based biosensors. (a) Basal FRET demonstrating agonist-
independent activity of β2AR FlAsH-BRET-based biosensors. Data represent results of three independent experiments. Error bars represent mean ± SE. One-way 
analysis of variance (ANOVA) was performed followed by Dunnett’s post hoc test. (B) Assessment of cAMP accumulation using the H188 FRET-based EPAC  
sensor in response to 10 µM isoproterenol. The ΔFRET ratio was obtained by subtracting the averaged isoproterenol stimulated FRET ratio by the averaged basal 
FRET ratio. One-way ANOVA was performed on results from three independent experiments followed by Dunnett’s post hoc test; asterisk represents *p ≤ 0.05.  
(c) Representative western blot probing activation of the ERK1/2 mitogen-activated protein kinase signaling pathway. HEK 293 SL cells were transiently transfected 
with the wild-type or recombinant β2AR constructs. Cells were stimulated with vehicle (−) or 10 µM isoproterenol (+) for 5 min. Cell lysates were collected and a 
western blot was performed using an ERK1/2 monoclonal rabbit primary antibody followed by an anti-rabbit secondary antibody conjugated to the horseradish 
peroxidase substrate. Phospho-ERK1/2 is shown in the upper panel while total ERK1/2 is shown in the lower panel. Data are representative of three independent 
experiments.
FigUre 4 | assessment of the agonist-induced conformational change in the intracellular surface of the β2-adrenergic receptor (β2ar). (a) Basal 
BRET for the panel of eight β2AR FlAsH-BRET-based biosensors. For each recombinant receptor, basal BRET readings were calculated after having corrected them 
for spectral overlap by subtracting the BRET ratio obtained from unlabeled receptors expressing solely the donor from basal BRET readings of the recombinant 
receptors. Six technical replicates were performed and subsequently averaged; error bars represent mean ± SE. One-way analysis of variance (ANOVA) was 
performed followed by Dunnett’s post hoc test. (B) Conformational changes within the cytoplasmic region of the β2AR in response to isoproterenol were measured. 
ΔBRET was calculated by subtracting averaged pre-injection BRET from post-injection readings. All readings were taken using the Tristar multimode plate reader 
(Berthold Technologies). Data represent means of three or more independent experiments; error bars represent mean ± SE. Two-way ANOVA was performed 
followed by Bonferroni corrected t-tests. Asterisks represent **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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resUlTs
Biosensor Validation
We constructed a number of FlAsH-BRET biosensors in the 
β2AR with a FlAsH-binding site engineered into various intra- 
cellular sites and Renilla luciferase placed on the carboxy 
terminus (Figure 1). If the biosensor components are positioned 
at appropriate sites within the receptor then this would allow 
profiling of conformational changes in the receptor upon ligand 
stimulation. In order for our intramolecular BRET constructs 
FigUre 5 | BreT kinetics in the second and third intracellular loops of the β2-adrenergic receptor (β2ar). HEK 293 SL cells transiently expressing the ICL2 
and ICL3 β2AR biosensors were labeled with the FlAsH reagent. (a) WT untagged receptor, (B) ICL2 p1, (c) ICL2 p2, (D) ICL3 p1, (e) ICL3 p2, and (F) ICL3 p3. Open 
boxes refer to vehicle and solid boxes refer to isoproterenol treatment. Basal BRET was captured prior to the injection of the full agonist, 10 µM isoproterenol. After 
ligand stimulation, data were continuously captured to observe the corresponding change in the BRET signal. The BRET ratio was calculated by dividing the 
fluorescence by the luminescence and plotted as a function of time. The dotted line represents the time at which the injection took place. The inset at the top right 
corner of each graph zooms in at the time points close to the injection. The data are representative of three or more independent experiments.
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to be meaningful tools for the study of receptor conformational 
dynamics, recombinant receptors must maintain their native 
function. If they do not function in a manner similar to the 
wildtype receptor, then conformational analysis will be meaning-
less. Immunofluorescence was first used to verify the surface 
localization of the recombinant receptors generated. An anti-HA 
antibody was used to label the recombinant receptors, followed 
by an Alexa fluor-488 conjugated secondary antibody. As illus-
trated in Figure 2, almost all the FlAsH-tagged β2AR constructs 
trafficked to the cell surface. Receptors tagged within the second 
intracellular loop were less robustly expressed compared to the 
wild type. However, the fluorescence intensity for all other posi-
tions was similar to the wild type providing us with at least six 
positions to carry forward.
Next, to further validate the functionality of each construct, 
we measured isoproterenol-mediated cAMP accumulation as 
well as ERK1/2 MAPK activation. We studied the relative accu-
mulation of cAMP as an indication of Gαs activation using the 
H188 FRET-based EPAC sensor. FRET was used as BRET-based 
EPAC biosensors could not be used with the BRET-based con-
formational biosensors (as both would be activated). As shown 
in Figures  3A,B, the majority of constructs displayed similar 
levels of cAMP accumulation (measured as a decrease in FRET) 
as compared to the untagged wild-type receptor. As the β2AR 
shows agonist-independent basal activity, we examined both 
basal (Figure  3A) and agonist-stimulated FRET (Figure  3B). 
We observed that certain sensor positions exhibited high basal 
activity as shown as the reduced FRET ratio at baseline. This may 
have been as a result of higher expression levels of these biosensors. 
For example, the C-tail P3 position may seem as though there is 
less cAMP production than the wild type in response to agonist; 
however, the lack of a robust decrease in FRET as a response to 
agonist is probably due to having attained the threshold of detec-
tion at basal levels.
We then examined a more distal readout of receptor function-
ality; the β2AR-mediated MAPK (Raf/Ras/MEK/ERK) signaling 
pathway that has been previously characterized by various groups 
(22, 23). As demonstrated by Figure  3C, all the recombinant 
β2AR constructs exhibited MAPK activation at similar intensities 
as the wild-type receptor. As a result, the third intracellular loop 
sensors as well as the C-tail sensors passed the validation stage 
although some caution again must be taken when interpreting 
results using the sensors engineered into the second intracellular 
loop. It must be noted here that all our transfections were tran-
sient and no attempt was made to normalize levels of expression 
per se.
BreT Measurements
Next, we measured basal BRET between the FlAsH-labeled 
receptors and the C-tail luciferase. Basal BRET or the BRET 
ratio after it has been corrected for spectral overlap of the donor 
and acceptor channels was determined by subtracting BRET 
where cells were not labeled with FlAsH. All receptor biosen-
sors showed basal BRET to varying degrees (Figure  4A). The 
FigUre 6 | BreT kinetics in the c-terminal β2-adrenergic receptor (β2ar) Flash constructs as well as in aT1r and FP biosensors. HEK 293 SL cells 
transiently transfected with the three C-tail β2AR recombinant biosensors or with FP ICL3 p4 or AT1R ICL3 p3 and C-tail p1 and then labeled with the FlAsH reagent. 
(a) C-tail p1, (B) C-tail p2, (c) C-tail p3, (D) FP ICL3 p4, (e) AT1R ICL3 p3, and (F) AT1R C-taol p1. Open boxes refer to vehicle and solid boxes refer to agonist 
treatment. Basal BRET was captured prior to the injection of each receptor’s respective full agonist, 10 µM isoproterenol, 1 µM PGF2α, or 1 µM angiotensin II. After 
ligand stimulation, data were continuously captured to observe the corresponding change in the BRET signal. The BRET ratio was calculated by dividing the 
fluorescence by the luminescence and plotted as a function of time. The dotted line represents the time at which the injection took place. The inset at the top right 
corner of each graph zooms in at the time points close to the injection. Measurements were recorded on 40,000 cells except for the AT1R C-tail p1 where 30,000 
cells were used. All readings were taken using the Tristar multimode plate reader (Berthold Technologies) except the AT1R C-tail p1 which was assayed on the Victor 
X Light (Perkin Elmer). The data are representative of three or more independent experiments.
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larger the basal BRET, the closer the donor–acceptor pair was 
at the outset. As a result, there is a greater dynamic range to 
capture relative changes in receptor conformation. The β2AR 
biosensor with the greatest basal BRET was the third position 
within the C-tail. There was a position-dependent increase in the 
basal BRET, as one moves farther down the tail of the receptor, 
as acceptor and donor moieties get closer together. As for the 
third loop, the second position showed the largest basal BRET 
which is in accordance to its position in the middle of the loop 
(Figure 4A).
ΔBRET in response to ligand was measured by subtracting the 
averaged post-injection BRET from the averaged pre-injection 
BRET readings. BRET ratios could potentially increase or decrease 
depending on the ligand used and the subsequent conforma- 
tion adopted by the receptor. It was hoped that our biosensors 
would differentially respond to ligands and provide a conforma-
tional fingerprint to better understand the dynamic nature of the 
receptor which could be exploited for validating new drugs in 
early phases of development. Of all the biosensors tested, only 
the C-tail positions P2 and P3 showed a robust conformational 
change upon isoproterenol stimulation (Figure 4B). The lack of 
response in ICL3 was somewhat of a surprise but the functional 
data (Figures 2 and 3) suggested that ICL2 sensors may not be 
correctly folded.
In order to make a comprehensive assessment of the isopro- 
terenol induced responses of the β2AR biosensors, we also 
examined the underlying kinetics. As mentioned, neither the 
second or third loop positions captured a sustained confor-
mational change in response to isoproterenol (Figures 4B and 
5). Oddly, a small spike was a consistent feature of the ligand-
induced response in these sensors with the exception of ICL3 P1 
(Figures 5D–F). The presence of this spike was not an artifact 
originating from the sampling instrument as no such spikes 
were seen when vehicle was similarly injected and it was also 
absent from kinetic traces of the wild-type receptor expressing 
RlucII with no FlAsH-binding sequences (Figure  5A). The 
C-tail P1 sensor displayed similar features as the second and 
third loop positions (Figures 5 and 6A). However, the responses 
in the other C-tail sensors were much more robust and sustained 
(Figures  6B,C). We have previously analyzed responses to 
ligand in both FP (11) and in the AT1R (17). Responses in ICL3 
in AT1R and FP were both robust and sustained (Figures 6D,E) 
compared to the β2AR. Further, robust sustained responses have 
also been detected in both ICL2 and the C-terminus of AT1R 
FigUre 7 | homology-based representation of the positioning of the Flash tag in three class a g protein-coupled receptors. (a) Homology model of 
the hβ2AR (P07550-1) based on PDB identifier: 2rh1A with truncated C-tail. Positions highlighted in orange correspond to the first position, in blue the second 
position, and in green the third position within each respective loop structure. (B) Homology model of the human angiotensin II type 1 receptor (P30556-1) modeled 
upon the existing crystal structure with PBD accession 4yayA, the C-tail was then truncated (25). The ICL3 p3 biosensor is shown in green. (c) Homology model of 
the human FP (P43088-1) based on the PBD ID: 3emlA. Insertion of the TC tag in ICL3 position 4 is shown in red. (D) Superimposing the models of the hβ2AR, 
AT1R, and FP. Overlay of three receptors reveals the relative similarities in the transmembrane domains and differences in the cytoplasmic regions. Approximately 20 
residues were removed from the N-terminus and the C-terminus was truncated to facilitate the visualization of the overall structure. Inset shows expanded versions 
of ICL2 (left) or ICL3 (right). The I-TASSER models (26, 27) were exported into PyMOL where the CCPGCC motifs were inserted at their respective positions and 
color coded to facilitate the visualization of the positioning of the FlAsH tags.
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[(17); Figure  6F]. Interestingly, no responses were detected 
in similar constructs built into either ICL2 or the C-tail of FP 
(data not shown). Taken together, our data paint a picture which 
highlights the conformational heterogeneity of different GPCRs 
in response to ligand stimulation.
DiscUssiOn
Crystal structures offer snapshot images of receptor structure 
that can be complemented using more dynamic measures such 
as RET approaches. Kobilka and coworkers reported that trans-
membrane domain VI experiences a 14  Å outward movement 
when comparing the inactive carazolol bound β2AR versus the 
active-Gαs bound crystal structure (24). We show here that three 
different GPCRs show distinct patterns of BRET in response 
to ligand even when biosensors are placed in similar positions 
(Figure 7).
For the β2AR, our data showed that ICL2 and ICL3 did not 
respond to the full agonist isoproterenol, whereas two of our C-tail 
biosensors exhibited sustained BRET responses. As the accep-
tor was progressively walked down the C-terminus, resonance 
energy was more efficiently transferred from donor to acceptor 
under basal conditions and this may explain why BRET was not 
detected in biosensors with acceptor and donor farther apart. This 
pattern was distinct in the AT1R and in FP receptor. The AT1R 
exhibits the most conformational heterogeneity in that sensors 
engineered into ICL2, ICL3, or the C-tail all reported robustly 
on conformational changes in response to either canonical (Ang 
II or Ang III) or biased (SI) ligands (17). Further, only ICL3 
biosensors reported responses upon stimulation with PGF2α in 
FP (11, data not shown for ICL2 or the C-tail). This may suggest 
that the movement of the intracellular loops in the β2AR or FP is 
constrained by a protein within the vicinity of the fifth, sixth or 
seventh transmembrane domain. Even if this constrained con- 
formation does not allow us to use these biosensors in this 
cellular background, it does highlight the advantage of using 
a six amino acid tag since this reduced size allows us to probe 
receptor conformation. For instance, if GFP or one of its variants 
were used instead of the FlAsH tag, perhaps the 238 amino acid 
(27  kDa) insertion would have significantly distorted receptor 
structure.
G protein-coupled receptors have many associated interacting 
partners that may pose conformational constraints on the recep-
tor which translates into distinct conformational profiles. One of 
the major differences between the three receptors is that both the 
AT1R and FP couple to Gαq whereas the β2AR couples to Gαs. 
The β2AR has also been reported to differentially couple to Gαi 
(28–30). It may be interesting to explore the propensity of the 
receptor to couple to different G proteins in a particular biological 
context. Such differential coupling may lead to distinct confor- 
mations adopted by the receptor. Alternatively, it is well known 
that all three GPCRs form oligomers (31–35). Homo-and heter-
odimers or larger oligomers are not fully characterized and their 
physiological roles are not fully understood. Perhaps the forma-
tion of such larger arrays imposes additional conformational 
constraints on the receptor. These effects must be considered as 
early as events occurring in receptor biosynthesis (36, 37). Further 
exploring the lifecycle of a receptor is merited since oligomeriza-
tion can alter several aspects of receptor function (37). Likewise, 
the β2AR experiences a high level of basal activity which some 
believe is due to the higher availability of G proteins and other 
effectors; proteins that might restrict receptor movement (38).
The length of intracellular loops in each receptor may also be 
related to measured conformational flexibility. The β2AR has a 
much longer third loop than the other two receptors. Taking this 
into account, we could imagine that the β2AR might be more free 
to adopt a larger range of conformations compared to the AT1R 
and FP (Figure 7). This may be a contributing factor explaining 
the different conformational patterns exhibited by all three recep-
tors. These receptors are all classed into the same family of class 
A GPCRs, yet, they show different conformational behaviors. 
It must also be noted that this method is limited by the orientation 
of the reporter proteins. If the receptor folds in such a way where 
the enzymatic pocket of RlucII orients itself facing away from the 
FlAsH tag, the transfer of resonance energy will be less efficient 
with respect to RET.
In conclusion, we have demonstrated that the β2AR, AT1R, 
and FP display distinct conformational signatures when assayed 
in HEK 293 cells. Certainly cell context will matter in such 
experiments. The introduction of these BRET-based biosensors 
into diverse cell types may result in the detection of multiple dif-
ferent conformations adopted by the receptor depending on the 
cellular and subcellular contexts. Such receptor-based biosensors 
will be portable in this regard. Combined with genome editing 
approaches, these sensors are simple tools that could be used 
to uncover the complex mechanisms of GPCR activation and 
function.
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